Literature DB >> 16226920

Correction of SMN2 Pre-mRNA splicing by antisense U7 small nuclear RNAs.

Csilla Madocsai1, Sharlene R Lim, Till Geib, Bianca J Lam, Klemens J Hertel.   

Abstract

Mutations in one of the duplicated survival of motor neuron (SMN) genes lead to the progressive loss of motor neurons and subsequent development of spinal muscular atrophy (SMA), a common, and usually fatal, hereditary disease. Homozygous absence of the telomeric copy (SMN1) correlates with development of SMA because differential splicing of the centromeric copy (SMN2) leads to exon 7 skipping and predominantly produces a biologically inactive protein isoform. To increase exon 7 inclusion of SMN2, we have designed a series of vectors that express modified U7 snRNAs containing antisense sequences complementary to the 3' splice site of SMN exon 8. Over 20 anti-SMN U7 snRNAs were tested for their ability to promote exon 7 inclusion in the SMN2 gene. Transient expression of anti-SMN U7 snRNAs in HeLa cells modulated SMN2 splicing to approximately 70% exon 7 inclusion in a sequence-specific and dose-dependent manner. Significantly, the administration of anti-SMN U7 snRNPs results in an increase in the concentration of SMN protein. These results suggest that modulation of SMN2 pre-mRNA splicing by modified U7 snRNAs provides a promising form of gene therapy for the treatment of SMA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16226920     DOI: 10.1016/j.ymthe.2005.08.022

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  46 in total

1.  The Silent Sway of Splicing by Synonymous Substitutions.

Authors:  William F Mueller; Liza S Z Larsen; Angela Garibaldi; G Wesley Hatfield; Klemens J Hertel
Journal:  J Biol Chem       Date:  2015-09-30       Impact factor: 5.157

Review 2.  Applicability of histone deacetylase inhibition for the treatment of spinal muscular atrophy.

Authors:  Sebastian Lunke; Assam El-Osta
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

3.  U7 snRNA-mediated correction of aberrant splicing caused by activation of cryptic splice sites.

Authors:  Hideki Uchikawa; Katsunori Fujii; Yoichi Kohno; Noriyuki Katsumata; Kazuaki Nagao; Masao Yamada; Toshiyuki Miyashita
Journal:  J Hum Genet       Date:  2007-09-13       Impact factor: 3.172

4.  Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model.

Authors:  Yimin Hua; Kentaro Sahashi; Gene Hung; Frank Rigo; Marco A Passini; C Frank Bennett; Adrian R Krainer
Journal:  Genes Dev       Date:  2010-07-12       Impact factor: 11.361

Review 5.  Repair of pre-mRNA splicing: prospects for a therapy for spinal muscular atrophy.

Authors:  Rachel Nlend Nlend; Kathrin Meyer; Daniel Schümperli
Journal:  RNA Biol       Date:  2010-07-01       Impact factor: 4.652

Review 6.  Spinal muscular atrophy: mechanisms and therapeutic strategies.

Authors:  Christian L Lorson; Hansjorg Rindt; Monir Shababi
Journal:  Hum Mol Genet       Date:  2010-04-13       Impact factor: 6.150

Review 7.  Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.

Authors:  Natalia N Singh; Brian M Lee; Christine J DiDonato; Ravindra N Singh
Journal:  Future Med Chem       Date:  2015-09-18       Impact factor: 3.808

8.  Trans-splicing-mediated improvement in a severe mouse model of spinal muscular atrophy.

Authors:  Tristan H Coady; Christian L Lorson
Journal:  J Neurosci       Date:  2010-01-06       Impact factor: 6.167

9.  Restoration of full-length SMN promoted by adenoviral vectors expressing RNA antisense oligonucleotides embedded in U7 snRNAs.

Authors:  Till Geib; Klemens J Hertel
Journal:  PLoS One       Date:  2009-12-08       Impact factor: 3.240

Review 10.  SMN-inducing compounds for the treatment of spinal muscular atrophy.

Authors:  Monique A Lorson; Christian L Lorson
Journal:  Future Med Chem       Date:  2012-10       Impact factor: 3.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.